MDM2 and mesothelioma: A majority of mesothelioma has a characteristic genetic alteration regarding the p53 expression and the present study suggested that a combinatory use of Ad-delE1B and a p53-augmenting MDM2 inhibitor was a therapeutic strategy for mesothelioma with the wild-type p53 genotype.